Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

zimmer biomet holdings inc. - ZBH

ZBH

Close Chg Chg %
93.17 1.06 1.14%

Closed Market

94.23

+1.06 (1.14%)

Volume: 2.30M

Last Updated:

Dec 5, 2025, 3:59 PM EDT

Trade Now

Company Overview: zimmer biomet holdings inc. - ZBH

ZBH Key Data

Open

$93.23

 Day Range

93.23 - 94.76

52 Week Range

85.34 - 114.44

 Market Cap

$18.46B

Shares Outstanding

198.18M

 Public Float

197.90M

Beta

0.62

 Rev. Per Employee

N/A

P/E Ratio

23.04

 EPS

$4.06

Yield

103.11%

 Dividend

$0.24

EX-DIVIDEND DATE

Sep 30, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

2.54M

  

ZBH Performance

1 Week
 
 -4.47%
 
1 Month
 
 5.27%
 
3 Months
 
 -11.89%
 
1 Year
 
 -13.76%
 
5 Years
 
 -36.21%
 

ZBH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About zimmer biomet holdings inc. - ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

ZBH At a Glance

Zimmer Biomet Holdings, Inc.
345 East Main Street
Warsaw, Indiana 46580
Phone 1-574-373-3333 Revenue 7.68B
Industry Medical Specialties Net Income 903.70M
Sector Health Technology 2024 Sales Growth 3.846%
Fiscal Year-end 12 / 2025 Employees 17,000
View SEC Filings

ZBH Valuation

P/E Current 23.039
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.83
Price to Sales Ratio 2.805
Price to Book Ratio 1.687
Price to Cash Flow Ratio 14.36
Enterprise Value to EBITDA 11.049
Enterprise Value to Sales 3.57
Total Debt to Enterprise Value 0.233

ZBH Efficiency

Revenue/Employee 451,682.353
Income Per Employee 53,158.824
Receivables Turnover 5.186
Total Asset Turnover 0.358

ZBH Liquidity

Current Ratio 1.906
Quick Ratio 0.994
Cash Ratio 0.214

ZBH Profitability

Gross Margin 62.794
Operating Margin 19.339
Pretax Margin 13.50
Net Margin 11.769
Return on Assets 4.217
Return on Equity 7.244
Return on Total Capital 4.791
Return on Invested Capital 5.088

ZBH Capital Structure

Total Debt to Total Equity 51.289
Total Debt to Total Capital 33.901
Total Debt to Total Assets 29.931
Long-Term Debt to Equity 44.368
Long-Term Debt to Total Capital 29.326
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Zimmer Biomet Holdings Inc. - ZBH

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
7.84B 6.94B 7.39B 7.68B
Sales Growth
+11.56% -11.44% +6.55% +3.85%
Cost of Goods Sold (COGS) incl D&A
2.96B 2.60B 2.73B 2.86B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.07B 926.40M 951.70M 996.30M
Depreciation
451.70M 399.60M 390.20M 404.40M
Amortization of Intangibles
615.70M 526.80M 561.50M 591.90M
COGS Growth
+6.66% -12.00% +5.00% +4.60%
Gross Income
4.88B 4.34B 4.66B 4.82B
Gross Income Growth
+14.74% -11.10% +7.47% +3.40%
Gross Profit Margin
+62.28% +62.52% +63.06% +62.79%
2021 2022 2023 2024 5-year trend
SG&A Expense
3.63B 3.10B 3.28B 3.34B
Research & Development
497.20M 406.00M 458.70M 437.40M
Other SG&A
3.13B 2.70B 2.82B 2.90B
SGA Growth
+7.03% -14.51% +5.62% +1.85%
Other Operating Expense
- - 53.10M 33.80M
-
Unusual Expense
585.00M 703.30M 201.70M 326.40M
EBIT after Unusual Expense
614.00M 499.90M 1.19B 1.16B
Non Operating Income/Expense
12.20M 67.70M 77.30M 85.10M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
207.80M 164.10M 195.30M 207.10M
Interest Expense Growth
-1.70% -21.03% +19.01% +6.04%
Gross Interest Expense
207.80M 164.10M 195.30M 207.10M
Interest Capitalized
- - - -
-
Pretax Income
418.40M 403.50M 1.07B 1.04B
Pretax Income Growth
+252.48% -3.56% +164.51% -2.88%
Pretax Margin
+5.34% +5.81% +14.43% +13.50%
Income Tax
16.30M 112.30M 42.20M 131.40M
Income Tax - Current - Domestic
42.60M 191.40M 20.00M 25.30M
Income Tax - Current - Foreign
123.40M (14.70M) 118.50M 153.80M
Income Tax - Deferred - Domestic
(137.40M) (73.20M) (141.90M) (72.00M)
Income Tax - Deferred - Foreign
(12.30M) 8.80M 45.60M 24.30M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
402.10M 291.20M 1.03B 905.20M
Minority Interest Expense
500.00K 1.00M 1.10M 1.50M
Net Income
401.60M 290.20M 1.02B 903.70M
Net Income Growth
+389.13% -27.74% +252.86% -11.75%
Net Margin Growth
+5.12% +4.18% +13.85% +11.77%
Extraordinaries & Discontinued Operations
- - - (58.80M)
-
Discontinued Operations
- - - (58.80M)
-
Net Income After Extraordinaries
401.60M 231.40M 1.02B 903.70M
Preferred Dividends
- - - -
-
Net Income Available to Common
401.60M 231.40M 1.02B 903.80M
EPS (Basic)
1.9252 1.104 4.9066 4.45
EPS (Basic) Growth
+386.92% -42.66% +344.44% -9.31%
Basic Shares Outstanding
208.60M 209.60M 208.70M 203.10M
EPS (Diluted)
1.9088 1.1003 4.8832 4.4326
EPS (Diluted) Growth
+384.47% -42.36% +343.81% -9.23%
Diluted Shares Outstanding
210.40M 210.30M 209.70M 203.90M
EBITDA
2.27B 2.13B 2.34B 2.48B
EBITDA Growth
+22.84% -6.04% +9.82% +6.10%
EBITDA Margin
+28.92% +30.69% +31.63% +32.31%

Snapshot

Average Recommendation HOLD Average Target Price 102.417
Number of Ratings 31 Current Quarters Estimate 2.396
FY Report Date 12 / 2025 Current Year's Estimate 8.172
Last Quarter’s Earnings 1.90 Median PE on CY Estimate N/A
Year Ago Earnings 8.00 Next Fiscal Year Estimate 8.512
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 26 22 27 27
Mean Estimate 2.40 1.92 8.17 8.51
High Estimates 2.46 2.09 8.23 8.98
Low Estimate 2.35 1.78 8.12 8.26
Coefficient of Variance 1.12 3.56 0.34 1.52

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 6 8
OVERWEIGHT 3 3 3
HOLD 19 19 16
UNDERWEIGHT 0 0 0
SELL 2 2 2
MEAN Hold Hold Overweight

Insider Actions for Zimmer Biomet Holdings Inc. - ZBH

Date Name Shares Transaction Value
Sep 16, 2025 Sang Yi Group President, Asia Pacific 18,584 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.58 per share 1,924,930.72
Apr 4, 2025 JehanZeb Noor See remarks below. 19,875 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Lori Winkler SVP and CHRO 7,040 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Wilfred van Zuilen Group Pres, EMEA 9,545 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Ivan Tornos President and CEO; Director 57,269 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Paul Stellato VP, Controller & CAO 2,458 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mark Bezjak President, Americas 8,829 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Suketu P. Upadhyay Exec. VP, CFO 19,090 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Chad F. Phipps Sr. VP/Gen Counsel/Secretary 7,875 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Suketu P. Upadhyay Exec. VP, CFO 21,622 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Ivan Tornos President and CEO; Director 40,014 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $101 per share 4,041,414.00
Feb 20, 2025 Sang Yi Group President, Asia Pacific 11,138 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Suketu P. Upadhyay Exec. VP, CFO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Mark Bezjak President, Americas N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Rachel H. Ellingson Chief Administrative Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Rachel H. Ellingson Chief Administrative Officer 5,572 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Rachel H. Ellingson Chief Administrative Officer 10,831 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $101 per share 1,093,931.00
Feb 20, 2025 Rachel H. Ellingson Chief Administrative Officer 12,623 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Chad F. Phipps Sr. VP/Gen Counsel/Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Chad F. Phipps Sr. VP/Gen Counsel/Secretary 10,158 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Zimmer Biomet Holdings Inc. in the News